Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system

Although EML4-ALK transforming fusion gene is represented in only 8% of non-small cell lung cancer (NSCLC) cases, its expression is partly responsive for the failure of current NSCLC treatments. Preventing secondary mutation of the ALK protein through direct gene manipulation could overcome NSCLC dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siwen, Liu, Yuxi, Rui, Yalan, Tang, Liping, Achilefu, Samuel, Gu, Yueqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956997/
https://www.ncbi.nlm.nih.gov/pubmed/29774063
http://dx.doi.org/10.7150/thno.24469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956997/
https://www.ncbi.nlm.nih.gov/pubmed/29774063
http://dx.doi.org/10.7150/thno.24469

Ejemplares similares